Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

In recent decades, in silico absorption, distribution, metabolism, excretion (ADME), and
toxicity (T) modelling as a tool for rational drug design has received considerable attention …

The aim of this tutorial is to introduce the concept of physiologically based pharmacokinetic
(PBPK) modeling to individuals in the pharmaceutical industry who may be relatively new to …

This document was developed to enable greater consistency in the practice, application,
and documentation of Model‐Informed Drug Discovery and Development (MID3) across the …

Natural products with polypharmacological profiles have demonstrated promise as novel
therapeutics for various complex diseases, including cancer. Currently, many gaps exist in …

Background: Therapeutic drug monitoring (TDM) and model-informed precision dosing
(MIPD) have greatly benefitted from computational and mathematical advances over the …

Modeling and simulation emerges as a fundamental asset of drug development. Mechanistic
modeling builds upon its strength to integrate various data to represent a detailed structural …

Drug development in oncology commonly exploits the tools of molecular biology to gain
therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) …

Recent growth in annual new therapeutic entity (NTE) approvals by the US Food and Drug
Administration (FDA) suggests a positive trend in current research and development (R&D) …

Natural products with diverse chemical scaffolds have been recognized as an invaluable
source of compounds in drug discovery and development. However, systematic …